Cancer vaccine - Aixlie

Drug Profile

Cancer vaccine - Aixlie

Alternative Names: HER-2-VAX; HER-2/neu vaccine - Aixlie

Latest Information Update: 14 Aug 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ohio State University
  • Developer Aixlie Pharmaceuticals; Arkios BioDevelopment International; Ohio State University
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 14 Aug 2003 Discontinued - Phase-I for Breast cancer in USA (unspecified route)
  • 08 Feb 2001 HER-2-VAXTM is available for licensing (
  • 28 Nov 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top